The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Prognostic value of bcl-2 expression in invasive breast cancer
Open accessAbstract
Expression of the bcl-2 proto-oncogene was studied immunohistochemically in 251 invasive ductal breast carcinomas (median follow-up time 91 months, range 24-186 months) and the results were correlated with clinicopathological data and prognostic variables. Sixty-three (25%) tumours were scored bcl-2 negative and 188 (75%) tumours were bcl-2 positive. No relationship could be observed between bcl-2 status and tumour grade, pTNM staging or menopausal status. A strong positive relationship was demonstrated between bcl-2 immunoreactivity and oestrogen receptor status (P < 0.001) and progesterone receptor status (P < 0.001). No prognostic value was demonstrated for bcl-2 expression on disease-free survival and overall survival in axillary node-negative breast cancer patients. However, in axillary node-positive breast cancer patients multivariate analysis demonstrated absence of bcl-2 expression to be independently related to shortened disease-free survival (P = 0.003) and shortened overall survival (P < 0.001). Our results suggest a potential important role for bcl-2 expression as a modulator of response to adjuvant therapy in breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death
Oltval, Z. N., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)90509-o · Cited by 6,003
BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death.
Hockenbery, D. M., Zutter, M., Hickey, W., Nahm, M., & Korsmeyer, S. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.16.6961 · Cited by 1,252
McDonnell, T. J., Deane, N., Platt, F. M., Nunez, G., Jaeger, U., McKearn, J. P., & Korsmeyer, S. J. (1989) · Cell · doi:10.1016/0092-8674(89)90174-8 · Cited by 1,213 · cited 1×
“In transgenic mice bct-2 has been shown to prolong cell survival (McDonnell et al., 1989; Strasser et al., 1990).”
BackgroundNuñez, G., London, L., Hockenbery, D., Alexander, M., McKearn, J. P., & Korsmeyer, S. J. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.9.3602 · Cited by 899
Cited by
Prognostic Factors in Breast Cancer: College of American Pathologists Consensus Statement 1999
Fitzgibbons, P. L., Page, D. L., Weaver, D., Thor, A. D., Allred, D. C., Clark, G. M., Ruby, S. G., O'Malley, F., Simpson, J. F., Connolly, J. L., et al. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0966-pfibc · Cited by 1,016
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
and members of the Southeast Sweden Breast Cancer Group, Pérez-Tenorio, G., & Stål, O. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600126 · Cited by 394
Metadata
- Authors
- Hellemans, P., van Dam, P., Weyler, J., van Oosterom, A., Buytaert, P., & Van Marck, E.
- Venue
- British Journal of Cancer
- Published
- 1995-08
- Volume
- 72
- Issue
- 2
- Pages
- 354-360
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2039026077
- Cited by
- 187
- References
- 4
- FWCI
- 6.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic value of bcl-2 expression in invasive breast cancer. https://app.cochat.ai/papers/10.1038/bjc.1995.338
- The paper
- Hellemans, P., van Dam, P., Weyler, J., van Oosterom, A., Buytaert, P., & Van Marck, E. (1995). Prognostic value of bcl-2 expression in invasive breast cancer. British Journal of Cancer. https://doi.org/10.1038/bjc.1995.338
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.